NASDAQ:OBSVObseva Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Obseva SA Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.76 -0.02 (-0.72 %) (As of 07/10/2020 09:37 AM ET) Add Compare Share Today's Range$2.73Now: $2.77▼$2.8550-Day Range$2.98MA: $4.98▼$6.1552-Week Range$1.63Now: $2.77▼$11.08Volume82,045 shsAverage Volume1.48 million shsMarket Capitalization$134.30 millionP/E RatioN/ADividend YieldN/ABeta1.1 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age. The company was founded in 2012 and is headquartered in Plan-les-Ouates, Switzerland.Read More Beat the Market (BTM) Rank™ 4.3 Analyst's Opinion Consensus RatingObseva has received a consensus rating of Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.71, Obseva has a potential upside of 427.4% from its current price of $2.79.Amount of Analyst CoverageObseva has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.3 Community Rank Outperform VotesObseva has received 292 “outperform” votes. (Add your “outperform” vote.)Underperform VotesObseva has received 337 “underperform” votes. (Add your “underperform” vote.)Community SentimentObseva has received 53.58% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Obseva and other stocks. Vote “Outperform” if you believe OBSV will outperform the S&P 500 over the long term. Vote “Underperform” if you believe OBSV will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldObseva does not currently pay a dividend.Dividend GrowthObseva does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Obseva insiders have not sold or bought any company stock.Percentage Held by Institutions53.03% of the stock of Obseva is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Obseva are expected to grow in the coming year, from ($1.58) to ($1.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Obseva is -1.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Obseva is -1.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioObseva has a P/B Ratio of 2.76. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.3Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.64 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OBSV Previous Symbol CUSIPN/A CIK1685316 Webwww.obseva.com Phone41-22-552-3840Debt Debt-to-Equity Ratio0.69 Current Ratio2.87 Quick Ratio2.87Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.01 per share Price / Book2.74Profitability EPS (Most Recent Fiscal Year)($2.49) Net Income$-108,790,000.00 Net MarginsN/A Return on Equity-167.15% Return on Assets-91.89%Miscellaneous Employees43 Outstanding Shares48,570,000Market Cap$134.30 million Next Earnings Date8/5/2020 (Estimated) OptionableNot Optionable NASDAQ:OBSV Rates by TradingView Receive OBSV News and Ratings via Email Sign-up to receive the latest news and ratings for OBSV and its competitors with MarketBeat's FREE daily newsletter. Obseva (NASDAQ:OBSV) Frequently Asked Questions How has Obseva's stock been impacted by COVID-19 (Coronavirus)? Obseva's stock was trading at $2.57 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, OBSV shares have increased by 8.6% and is now trading at $2.79. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Obseva? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Obseva in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Obseva. When is Obseva's next earnings date? Obseva is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Obseva. How were Obseva's earnings last quarter? Obseva SA (NASDAQ:OBSV) announced its quarterly earnings data on Tuesday, May, 5th. The company reported ($0.48) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by $0.00. View Obseva's earnings history. What price target have analysts set for OBSV? 7 equities research analysts have issued 1 year price targets for Obseva's shares. Their forecasts range from $4.00 to $36.00. On average, they anticipate Obseva's stock price to reach $14.71 in the next year. This suggests a possible upside of 427.4% from the stock's current price. View analysts' price targets for Obseva. Has Obseva been receiving favorable news coverage? News articles about OBSV stock have been trending neutral on Friday, InfoTrie Sentiment reports. The research firm rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Obseva earned a media sentiment score of 0.5 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news about Obseva. Are investors shorting Obseva? Obseva saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 799,000 shares, an increase of 24.1% from the June 15th total of 644,000 shares. Based on an average daily trading volume, of 705,300 shares, the days-to-cover ratio is currently 1.1 days. Approximately 2.7% of the shares of the company are sold short. View Obseva's Current Options Chain. Who are some of Obseva's key competitors? Some companies that are related to Obseva include Atreca (BCEL), Corbus Pharmaceuticals (CRBP), Athersys (ATHX), Syndax Pharmaceuticals (SNDX), Legend Biotech (CALT), Syros Pharmaceuticals (SYRS), Crinetics Pharmaceuticals (CRNX), Neoleukin Therapeutics (NLTX), Catalyst Pharmaceuticals (CPRX), Clovis Oncology (CLVS), Urogen Pharma (URGN), NextCure (NXTC), Protagonist Therapeutics (PTGX), Viking Therapeutics (VKTX) and Mirum Pharmaceuticals (MIRM). View all competitors. What other stocks do shareholders of Obseva own? Based on aggregate information from My MarketBeat watchlists, some companies that other Obseva investors own include Gilead Sciences (GILD), Allena Pharmaceuticals (ALNA), Inovio Pharmaceuticals (INO), Opko Health (OPK), Viking Therapeutics (VKTX), Sorrento Therapeutics (SRNE), Trevena (TRVN), Zosano Pharma (ZSAN), Corbus Pharmaceuticals (CRBP) and SCYNEXIS (SCYX). Who are Obseva's key executives? Obseva's management team includes the following people: Dr. Ernest Loumaye, Co-Founder, CEO & Director (Age 67)Mr. Timothy M. Adams, Chief Financial Officer (Age 59)Dr. Jean-Pierre Gotteland Ph.D., Chief Scientific Officer and Head of R&D (Age 54)Mr. Mario Vincent Corso, Sr. Director of Investor RelationsDr. Elke Bestel M.D., Chief Medical Officer & Head of Pharmacovigilance (Age 53) When did Obseva IPO? (OBSV) raised $98 million in an IPO on Thursday, January 26th 2017. The company issued 6,500,000 shares at $14.00-$16.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO. What is Obseva's stock symbol? Obseva trades on the NASDAQ under the ticker symbol "OBSV." How do I buy shares of Obseva? Shares of OBSV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Obseva's stock price today? One share of OBSV stock can currently be purchased for approximately $2.79. How big of a company is Obseva? Obseva has a market capitalization of $135.51 million. The company earns $-108,790,000.00 in net income (profit) each year or ($2.49) on an earnings per share basis. Obseva employs 43 workers across the globe. What is Obseva's official website? The official website for Obseva is www.obseva.com. How can I contact Obseva? Obseva's mailing address is Chemin des Aulx 12 Plan-les-Ouates, Geneva V8, 1228. The company can be reached via phone at 41-22-552-3840 or via email at [email protected] This page was last updated on 7/10/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
